Rachel McMinn
CIK 1606302 · Chief Executive Officer · last filed 2026-03-30
Rachel McMinn is a Chief Executive Officer who has filed 24 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing shows the insider sold $74.0K of NGNE on Mar 30, 2026. Across all open-market trades the lifetime net is +$354.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $39.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$39.12M
2
24
$354.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NGNE | Chief Executive Officer | 1,344,307 | $29.10 | $39.12M | $895.0K | 5 | 2026-03-30 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Chief Strategy Officer | 16,875 | $19.00 | $320.6K | -$540.7K | 19 | 2017-10-04 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-30 | NGNE | Sell (S) | −3,352 | -$74.0K | EDGAR |
| 2026-02-24 | NGNE | Grant (A) | +25,900 | $0 | EDGAR |
| 2025-03-28 | NGNE | Grant (A) | +23,900 | $0 | EDGAR |
| 2024-11-25 | NGNE | Buy (P) | +47,500 | $969.0K | EDGAR |
| 2024-03-14 | NGNE | Grant (A) | — | $0 | EDGAR |
| 2017-10-04 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −283 | -$16.7K | EDGAR |
| 2017-08-02 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −130 | -$16.0K | EDGAR |
| 2017-07-05 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −257 | -$31.3K | EDGAR |
| 2017-05-03 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −114 | -$12.9K | EDGAR |
| 2017-04-05 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −257 | -$29.6K | EDGAR |